POINT Biopharma to Participate in Upcoming Investor Conferences
February 02, 2023 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
January 12, 2023 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
November 29, 2022 07:30 ET
|
POINT Biopharma
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model ...
POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
November 14, 2022 07:15 ET
|
POINT Biopharma
INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
November 14, 2022 07:00 ET
|
POINT Biopharma
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...
ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177
October 24, 2022 02:30 ET
|
ITM Isotope Technologies Munich SE
ONTARIO, CANADA, and MUNICH, GERMANY, October 24, 2022 – An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM),...
POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress
October 17, 2022 08:30 ET
|
POINT Biopharma
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA...
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock
September 16, 2022 16:30 ET
|
POINT Biopharma
INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 21:47 ET
|
POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
September 10, 2022 03:05 ET
|
POINT Biopharma
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR)...